Skip to content

Clinical trials

Phase 1 Adenocarcinoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Adenocarcinoma Phase: Phase 1 Country / region: United States Clear all

82 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20031
20051
20064
20071
20081
20093
20104
20118
20127
20135
20146
20152
20164
20176
20184
20191
20203
20213
20224
20233
20242
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed47
Terminated16
Recruiting9
Active, not recruiting3
Withdrawn3
Unknown status2
Enrolling by invitation1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)7
H. Lee Moffitt Cancer Center and Research Institute5
Blueprint Medicines Corporation3
Novartis Pharmaceuticals3
University of Pennsylvania3
M.D. Anderson Cancer Center2
Memorial Sloan Kettering Cancer Center2
Nuvectis Pharma, Inc.2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
Stanford University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Adenocarcinoma82
Neoplasms29
Carcinoma, Non-Small-Cell Lung21
Pancreatic Neoplasms20
Neoplasm Metastasis17
Colorectal Neoplasms13
Lung Neoplasms12
Carcinoma11
Prostatic Neoplasms11
Stomach Neoplasms11

Trials

Showing 1 to 25 of 82. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.